- Home
- CTOS vs GYRE Comparison
CTOS vs GYRE Comparison
Compare CTOS & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOS
- GYRE
- Stock Information
- Founded
- CTOS 1988
- GYRE 2002
- Country
- CTOS United States
- GYRE United States
- Employees
- CTOS N/A
- GYRE N/A
- Industry
- CTOS Diversified Commercial Services
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- CTOS Consumer Discretionary
- GYRE Health Care
- Exchange
- CTOS Nasdaq
- GYRE Nasdaq
- Market Cap
- CTOS 1.1B
- GYRE 1.1B
- IPO Year
- CTOS N/A
- GYRE N/A
- Fundamental
- Price
- CTOS $4.77
- GYRE $10.95
- Analyst Decision
- CTOS Buy
- GYRE
- Analyst Count
- CTOS 5
- GYRE 0
- Target Price
- CTOS $6.90
- GYRE N/A
- AVG Volume (30 Days)
- CTOS 655.6K
- GYRE 128.0K
- Earning Date
- CTOS 03-06-2025
- GYRE 11-13-2024
- Dividend Yield
- CTOS N/A
- GYRE N/A
- EPS Growth
- CTOS N/A
- GYRE N/A
- EPS
- CTOS N/A
- GYRE N/A
- Revenue
- CTOS $1,803,294,000.00
- GYRE $105,033,000.00
- Revenue This Year
- CTOS N/A
- GYRE $25.32
- Revenue Next Year
- CTOS $2.36
- GYRE $12.95
- P/E Ratio
- CTOS N/A
- GYRE N/A
- Revenue Growth
- CTOS N/A
- GYRE N/A
- 52 Week Low
- CTOS $3.03
- GYRE $8.26
- 52 Week High
- CTOS $7.00
- GYRE $26.37
- Technical
- Relative Strength Index (RSI)
- CTOS 48.00
- GYRE 48.93
- Support Level
- CTOS $4.55
- GYRE $9.51
- Resistance Level
- CTOS $4.75
- GYRE $11.11
- Average True Range (ATR)
- CTOS 0.19
- GYRE 0.85
- MACD
- CTOS -0.00
- GYRE 0.04
- Stochastic Oscillator
- CTOS 60.77
- GYRE 29.33
About CTOS Custom Truck One Source Inc.
Custom Truck One Source Inc is a one-stop-shop provider of specialty equipment in the electric utility transmission and distribution, forestry, telecom, waste management, rail, and infrastructure end-markets in North America. The company's segment includes Equipment Rental Solutions (ERS), Truck and Equipment Sales (TES), and Aftermarket Parts and Services (APS). It generates maximum revenue from the TES segment. Geographically, it derives a majority revenue from the United States.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.